^(161)Tb-PSMA放射性配体治疗前列腺癌研究进展  

Research Progress of ^(161)Tb-PSMA Radioligand Therapy for Prostate Cancer

作　　者：陈正国[1,2] 杨夏 肖力铭[1,2] 胡博森 刘芙岑 赵鹏 CHEN Zhengguo;YANG Xia;XIAO Liming;HU Bosen;LIU Fucen;ZHAO Peng(NHC Key Laboratory of Nuclear Technology Medical Transformation(Mianyang Central Hospital),Mianyang 621000,China;Department of Nuclear Medicine,Mianyang Central Hospital,Mianyang 621000,China;Institute of Nuclear Physics and Chemistry,Chinese Academy of Engineering Physics,Mianyang 621000,China;National Defense Technology College of Southwest University of Science and Technology,Mianyang 621010,China)

机构地区：[1]国家卫生健康委核技术医学转化重点实验室(绵阳市中心医院),绵阳621000 [2]绵阳市中心医院核医学科,绵阳621000 [3]中国工程物理研究院核物理与化学研究所,绵阳621000 [4]西南科技大学国防技术学院,绵阳621010

出　　处：《同位素》2024年第5期500-506,共7页Journal of Isotopes

基　　金：国家卫生健康委员会核技术医学转化重点实验室开放课题资助(2023HYX026);绵阳市中心医院孵化课题资助(2022FH011)。

摘　　要：前列腺特异性膜抗原(PSMA)放射性配体治疗(PRLT)已成为一种重要的新型疗法,尤其适合治疗常规疗法无法有效控制的转移性去势抵抗性前列腺癌(mCRPC),以镥-177(^(177)Lu)-PSMA-617为代表的PRLT具有良好的安全性,能有效延长mCRPC患者生存期,改善生活质量等优势。尽管^(177)Lu-PSMA-617治疗mCRPC取得成功,但仍有部分患者不敏感,甚至对治疗无响应,出现复发情况。铽-161(^(161)Tb)与177Lu均具有β-射线,但与^(177)Lu相比,其最大的优势在于释放针对小病灶治疗的俄歇电子和内转化电子,这种β-射线与俄歇电子的协同疗法,具有满足不同大小病灶治疗的优点,使得全球范围对^(161)Tb进行肿瘤治疗的关注度正在上升。本文将从^(161)Tb的制备、标记、质控、辐射剂量、临床前研究、临床研究以及展望等方面对^(161)Tb-PSMA研究进行综述,旨在为开展PRLT的医务人员及患者提供参考。Prostate specific membrane antigen(PSMA) radioligand therapy(PRLT) has become an important new therapy,especially suitable for the treatment of metastatic castration resistant prostate cancer(mCRPC) which cannot be effectively controlled by conventional therapy.PRLT,represented by Lutetium-177(^(177)Lu)-PSMA-617,has good safety,can effectively prolong the survival time of mCRPC patients,and improve their quality of life.Despite the success of ^(177)Lu-PSMA-617 in the treatment of mCRPC,some patients are still insensitive or even unresponsive to treatment,so the disease progresses and relapse is inevitable.Terbium-161(^(161)Tb) has the same β-rays as ^(177)Lu,but its biggest advantage compared with ^(177)Lu is to release Auger electrons and internal conversion electrons for the treatment of small lesions.This synergistic therapy of β-rays and Auger electron has the advantage of meeting the treatment of lesions of different sizes,which has led to a rising interest in ^(161)Tb for tumor therapy worldwide.In this paper,the preparation,labeling,quality control,radiation dose,preclinical research,clinical research and prospects of ^(161)Tb-PSMA will be reviewed,aiming to provide references for medical staff and patients who carry out PRLT.

关 键 词：放射性配体治疗 转移性去势抵抗性前列腺癌 铽-161 前列腺特异性膜抗原 

分 类 号：TL923[核科学技术—核燃料循环与材料] TL99